Spotlight on Impactful Research: Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Liver Transplantation Recipients.
作者信息
Loy Veronica
机构信息
Department of Medicine, Medical College of Wisconsin Milwaukee WI.
出版信息
Clin Liver Dis (Hoboken). 2021 Feb 28;17(2):53-56. doi: 10.1002/cld.962. eCollection 2021 Feb.
Abstract
摘要
相似文献
1
Spotlight on Impactful Research: Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Liver Transplantation Recipients.聚焦有影响力的研究：低剂量缬更昔洛韦用于中危肝移植受者的巨细胞病毒预防
Clin Liver Dis (Hoboken). 2021 Feb 28;17(2):53-56. doi: 10.1002/cld.962. eCollection 2021 Feb.
2
Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.低剂量与标准剂量缬更昔洛韦预防中危肾移植受者巨细胞病毒病的疗效与安全性
Exp Clin Transplant. 2016 Oct;14(5):526-534. doi: 10.6002/ect.2015.0305. Epub 2016 Jun 15.
3
Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.接受缬更昔洛韦预防治疗的高危肝移植受者与接受更昔洛韦预防治疗的高危肝移植受者相比，巨细胞病毒感染发生率增加。
Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.
4
Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?盐酸缬更昔洛韦（万赛维）对肝移植受者的巨细胞病毒感染有有效的预防作用吗？
Transplant Proc. 2005 Sep;37(7):3182-6. doi: 10.1016/j.transproceed.2005.07.032.
5
Extended Efficacy of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients: Two-Year Follow-Up.低剂量缬更昔洛韦预防中危肾移植受者巨细胞病毒病的长期疗效：两年随访
Exp Clin Transplant. 2019 Jun;17(3):339-343. doi: 10.6002/ect.2018.0020. Epub 2019 Jan 21.
6
Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.吗替麦考酚酯联合低剂量更昔洛韦预防肾移植术后抗淋巴细胞球蛋白诱导治疗患者巨细胞病毒感染的临床研究。
Transpl Immunol. 2019 Oct;56:101226. doi: 10.1016/j.trim.2019.101226. Epub 2019 Jul 22.
7
Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.基于体重的缬更昔洛韦剂量方案用于儿科实体器官移植受者巨细胞病毒预防的疗效和安全性。
Transplantation. 2019 Aug;103(8):1730-1735. doi: 10.1097/TP.0000000000002632.
8
Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.在接受来自巨细胞病毒阳性供体的肾脏移植的巨细胞病毒阴性受者中，使用缬更昔洛韦进行长期低剂量预防可实现血清转化并预防巨细胞病毒疾病。
Transplant Proc. 2017 Dec;49(10):2280-2284. doi: 10.1016/j.transproceed.2017.10.004.
9
Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis.接受缬更昔洛韦预防巨细胞病毒感染的肾移植受者白细胞减少症的发病率及危险因素
Prog Transplant. 2018 Jun;28(2):124-133. doi: 10.1177/1526924818765798. Epub 2018 Mar 20.
10
Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.更昔洛韦预防巨细胞病毒与高剂量伐昔洛韦相比可减少肾移植后纤维化：一项平行组、开放标签、随机对照试验。
BMC Infect Dis. 2018 Nov 15;18(1):573. doi: 10.1186/s12879-018-3493-y.
引用本文的文献
1
Management of cytomegalovirus infection after liver transplantation.肝移植术后巨细胞病毒感染的管理
World J Transplant. 2024 Sep 18;14(3):93209. doi: 10.5500/wjt.v14.i3.93209.
本文引用的文献
1
The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients.复发性巨细胞病毒感染对实体器官移植受者长期生存的影响。
Transpl Infect Dis. 2019 Dec;21(6):e13189. doi: 10.1111/tid.13189. Epub 2019 Oct 18.
2
Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.实体器官移植受者巨细胞病毒感染：美国移植感染病学会实践社区指南。
Clin Transplant. 2019 Sep;33(9):e13512. doi: 10.1111/ctr.13512. Epub 2019 Mar 28.
3
Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.低剂量缬更昔洛韦用于中危风险肝移植受者的巨细胞病毒预防。
Liver Transpl. 2018 May;24(5):616-622. doi: 10.1002/lt.25047.
4
Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.肝移植术后巨细胞病毒感染的研究进展
Pharmacotherapy. 2017 Oct;37(10):1258-1271. doi: 10.1002/phar.1987. Epub 2017 Sep 3.
5
Infection in Organ Transplantation.器官移植中的感染
Am J Transplant. 2017 Apr;17(4):856-879. doi: 10.1111/ajt.14208. Epub 2017 Mar 10.
6
7
Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.接受膦甲酸钠治疗的耐更昔洛韦或难治性巨细胞病毒感染移植受者的结局
Transplantation. 2016 Oct;100(10):e74-80. doi: 10.1097/TP.0000000000001418.
8
Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.实体器官移植受者中耐更昔洛韦的巨细胞病毒感染：一项单中心回顾性队列研究。
Transpl Infect Dis. 2016 Jun;18(3):390-5. doi: 10.1111/tid.12537. Epub 2016 Jun 9.
9
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.更新的实体器官移植中巨细胞病毒管理的国际共识指南。
Transplantation. 2013 Aug 27;96(4):333-60. doi: 10.1097/TP.0b013e31829df29d.
10
CMV: Prevention, Diagnosis and Therapy.巨细胞病毒：预防、诊断与治疗。
Am J Transplant. 2013 Feb;13 Suppl 3:24-40; quiz 40. doi: 10.1111/ajt.12006.
Zotero 插件